Search company, investor...

Vector Development

Founded Year



Series A | Alive

Total Raised


Last Raised

$54M | 24 yrs ago

About Vector Development

Vector Development is a development firm.

Headquarters Location

4350 North Fairfax Drive Suite 350

United States




Latest Vector Development News

Global Viral Vector Development Market is on track to attain a noteworthy value of US$ 4.1 billion by 2033 at a CAGR of 18.7% | FMI

Feb 14, 2024

| FMI Viral Vector Development Market The global viral vector development market size is poised for remarkable growth, with a projected valuation of US$ 730.7 Million by the end of 2023 and an anticipated expansion at a Compound Annual Growth Rate (CAGR) of 18.7%, reaching a staggering US$ 4.1 Billion by the year 2033. These insights are derived from a recent study conducted by Future Market Insights. The study highlights that adeno-associated viral vectors (AAV) are at the forefront of this market, expected to capture approximately 37.0% of the global market share in 2023. AAVs have emerged as a leading force in viral vector development, playing a pivotal role in various applications, including gene therapy and vaccine development. Key findings from the study indicate a robust and sustained demand for viral vector technologies, driven by the increasing adoption of gene therapies and advancements in biotechnology. The versatility and efficacy of adeno-associated viral vectors have positioned them as a preferred choice among researchers and industry players. The anticipated growth in the viral vector development market signifies a paradigm shift in the healthcare and biotechnology landscape, with significant implications for the development of innovative therapies and treatments. Stakeholders in the pharmaceutical and biotech industries should closely monitor these trends, as they present substantial opportunities for investment and collaboration. “As the global demand for advanced therapies and personalized medicine continues to rise, viral vector development, especially the prominence of adeno-associated viral vectors, is expected to play a pivotal role in shaping the future of medical treatments,” said Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.). This comprehensive study provides valuable insights for industry stakeholders, investors, and decision-makers, offering a strategic outlook on the evolving landscape of viral vector development. The market dynamics and growth trajectory outlined in the report underscore the significance of continued research and innovation in this space. Key Takeaways: Gene therapy is vital to repair suppressed and malfunctioning genes in human cells or tissues and helps in returning the abnormality to a normal level. Viral vector technology is commonly utilized to cultivate the gene. Furthermore, this business has grown for many private players. For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process. When it comes to 2D planer technologies, scaling out of adherent cell systems is one of the common strategies that is applied until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period. The propelling synthesis of viral vectors utilizing cell culture technology has been modified successfully in order to satisfy the demands of both early and advanced clinical trial phases. Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen. At present, visible progress is being made within the generation of cell lines that are able to create inducible or constitutively expressed lentiviral vectors that grow in suspension. Over the past few years, the first batch of lentiviral vectors generated by reliable producer cell lines was utilized in a clinical trial setting. With extensive safety and efficiency, the data gathered from numerous clinical trials show that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period. Discover The Power Of Methodology-Driven Insights: Competitive Landscape: Over recent years, the market for the production of plasmid DNA and viral vector CDMO has become extremely competitive. This has resulted in the introduction of numerous companies in these industries. The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies. Key Companies Covered:

Vector Development Frequently Asked Questions (FAQ)

  • When was Vector Development founded?

    Vector Development was founded in 2000.

  • What is Vector Development's latest funding round?

    Vector Development's latest funding round is Series A.

  • How much did Vector Development raise?

    Vector Development raised a total of $54M.

  • Who are the investors of Vector Development?

    Investors of Vector Development include Warburg Pincus, AEA Investors and Deutsche Bank.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.